GB2377637A - Paroxetine methanesulphonate composition - Google Patents

Paroxetine methanesulphonate composition Download PDF

Info

Publication number
GB2377637A
GB2377637A GB0216752A GB0216752A GB2377637A GB 2377637 A GB2377637 A GB 2377637A GB 0216752 A GB0216752 A GB 0216752A GB 0216752 A GB0216752 A GB 0216752A GB 2377637 A GB2377637 A GB 2377637A
Authority
GB
United Kingdom
Prior art keywords
paroxetine
solution
methanesulfonate
paroxetine methanesulfonate
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0216752A
Other languages
English (en)
Other versions
GB0216752D0 (en
Inventor
Victor Witold Jacewicz
Michael William John Urquhart
Andrew Simon Craig
Deidre O'keefe
Neal Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB2377637(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9814316.7A external-priority patent/GB9814316D0/en
Priority claimed from GBGB9821732.6A external-priority patent/GB9821732D0/en
Priority claimed from GBGB9902935.7A external-priority patent/GB9902935D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of GB0216752D0 publication Critical patent/GB0216752D0/en
Publication of GB2377637A publication Critical patent/GB2377637A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GB0216752A 1998-07-02 1999-04-23 Paroxetine methanesulphonate composition Withdrawn GB2377637A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9814316.7A GB9814316D0 (en) 1998-07-02 1998-07-02 Novel compounds
GBGB9821732.6A GB9821732D0 (en) 1998-10-06 1998-10-06 Novel compound
GBGB9902935.7A GB9902935D0 (en) 1999-02-10 1999-02-10 Novel compound
GB0119695A GB2367003A (en) 1998-07-02 1999-04-23 Paroxetine methansulphonate compositions

Publications (2)

Publication Number Publication Date
GB0216752D0 GB0216752D0 (en) 2002-08-28
GB2377637A true GB2377637A (en) 2003-01-22

Family

ID=27269380

Family Applications (5)

Application Number Title Priority Date Filing Date
GB0216752A Withdrawn GB2377637A (en) 1998-07-02 1999-04-23 Paroxetine methanesulphonate composition
GB9909505A Revoked GB2336364B (en) 1998-07-02 1999-04-23 Paroxetine salt
GB9920332A Withdrawn GB2339428A (en) 1998-07-02 1999-04-23 Paroxetine methanesulfonate
GB0026487A Expired - Fee Related GB2352395B (en) 1998-07-02 1999-04-23 Paroxetine methanesulfonate
GB0119695A Withdrawn GB2367003A (en) 1998-07-02 1999-04-23 Paroxetine methansulphonate compositions

Family Applications After (4)

Application Number Title Priority Date Filing Date
GB9909505A Revoked GB2336364B (en) 1998-07-02 1999-04-23 Paroxetine salt
GB9920332A Withdrawn GB2339428A (en) 1998-07-02 1999-04-23 Paroxetine methanesulfonate
GB0026487A Expired - Fee Related GB2352395B (en) 1998-07-02 1999-04-23 Paroxetine methanesulfonate
GB0119695A Withdrawn GB2367003A (en) 1998-07-02 1999-04-23 Paroxetine methansulphonate compositions

Country Status (34)

Country Link
US (4) US6063927A (enExample)
EP (5) EP0970955B1 (enExample)
JP (1) JP2002519422A (enExample)
KR (1) KR20010053336A (enExample)
CN (1) CN1127502C (enExample)
AR (2) AR011759A1 (enExample)
AT (4) ATE251155T1 (enExample)
AU (4) AU3619199A (enExample)
BE (3) BE1012403A5 (enExample)
BR (1) BR9911682A (enExample)
CA (1) CA2269999A1 (enExample)
CH (1) CH689805A8 (enExample)
DE (5) DE29907248U1 (enExample)
DK (7) DK199900176U3 (enExample)
ES (4) ES2209428T3 (enExample)
FI (2) FI4209U1 (enExample)
FR (2) FR2780728B1 (enExample)
GB (5) GB2377637A (enExample)
GR (3) GR990100140A (enExample)
HU (1) HUP0102334A3 (enExample)
IE (5) IES81166B2 (enExample)
IL (1) IL140628A (enExample)
IT (1) IT1312540B1 (enExample)
LU (1) LU90388B1 (enExample)
NL (4) NL1011875C2 (enExample)
NO (1) NO319030B1 (enExample)
NZ (1) NZ509180A (enExample)
PL (1) PL345214A1 (enExample)
PT (4) PT1020464E (enExample)
SE (1) SE9901462A0 (enExample)
SI (3) SI0970955T1 (enExample)
SK (1) SK20262000A3 (enExample)
TR (1) TR200100054T2 (enExample)
WO (1) WO2000001694A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
BR9807625A (pt) * 1997-02-27 2000-02-22 Ajinomoto Kk Aparelho e processo para cristalização.
JP2002503248A (ja) * 1997-06-10 2002-01-29 シントン・ベスローテン・フェンノートシャップ ４−フェニルピペリジン化合物
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US20040028582A1 (en) * 1999-03-10 2004-02-12 Smithkline Beecham Corporation Crystallization process for producing fine crystal products
USPP12225P2 (en) 1999-06-01 2001-11-27 Florfis Ag Geranium plant named ‘Fislamda’
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
AU5078700A (en) * 1999-06-22 2001-01-09 Smithkline Beecham Plc Novel composition
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
EP1313474A2 (en) * 2000-08-28 2003-05-28 Synthon B.V. Paroxetine compositions and processes for making the same
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
US20040225128A1 (en) * 2001-08-02 2004-11-11 Callewaert George Leo Paroxetine isethionate salt, process of preparation and use in the treatment of depression
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
EP1874908B1 (en) * 2005-04-07 2014-06-11 Xy, Llc Method for reducing microorganisms in a flow path using diacetone alcohol
US20070112031A1 (en) * 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
CA2632149C (en) * 2005-12-01 2011-11-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US20100093749A1 (en) * 2007-03-09 2010-04-15 Novartis Ag Compounds
US8119688B2 (en) * 2007-09-19 2012-02-21 Xy, Llc Differential evaporation potentiated disinfectant system
US20100249166A1 (en) * 2007-09-19 2010-09-30 Xy, Inc. Differential evaporation potentiated disinfectant system
FR2926552B1 (fr) * 2008-01-23 2010-03-26 Biocodex Procede de preparation de particules de stiripentol ayant une granulometrie definie
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法
CN104523645A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 甲磺酸帕罗西汀片芯及其包衣片的制备方法
US11111373B2 (en) 2018-12-05 2021-09-07 Chi Mei Corporation Polymethacrylate composition and optical device made therefrom, and display apparatus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
WO1998056787A1 (en) * 1997-06-10 1998-12-17 Synthon B.V. 4-Phenylpiperidine compounds

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE99678C (enExample) *
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
GB8431478D0 (en) * 1984-12-13 1985-01-23 Beecham Group Plc Compounds
DE3680184D1 (de) * 1985-08-10 1991-08-14 Beecham Group Plc Verfahren zur herstellung von arylpiperidincarbinol.
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223430B1 (en) * 1985-10-21 1991-02-27 Honda Giken Kogyo Kabushiki Kaisha Method for controlling the solenoid current of a solenoid valve which controls the amount of suction of air in an internal combustion engine
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
EP0269383A3 (en) * 1986-11-21 1990-05-02 A.H. Robins Company, Incorporated 1-Aryloxy-4-[(4-aryl)-1-piperazinyl]-2-butanols useful as antiallergy agents
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
JPH06502854A (ja) * 1990-11-24 1994-03-31 ビーチャム・グループ・パブリック・リミテッド・カンパニー 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
EP0818990A1 (en) * 1995-04-03 1998-01-21 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
CA2220963A1 (en) * 1995-05-17 1996-11-21 Novo Nordisk A/S Process for preparing 4-aryl-piperidine derivatives
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
AU701386B2 (en) * 1995-10-31 1999-01-28 Merck & Co., Inc. Process for preparing substituted azetidinones
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP0812827B1 (en) * 1996-06-13 2009-09-02 Sumitomo Chemical Company, Limited Piperidine derivative as intermediates for the preparation of paroxetine and process for their preparation
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
EP1053234A1 (en) * 1998-02-06 2000-11-22 Smithkline Beecham Plc Salts of paroxetine
CA2323896A1 (en) * 1998-03-16 1999-09-23 Andrew Simon Craig Crystalline form of paroxetine
SK15032000A3 (sk) * 1998-04-09 2001-04-09 Smithkline Beecham Plc Maleínan paroxetínu, spôsob jeho výroby a jeho použitie
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
WO1998056787A1 (en) * 1997-06-10 1998-12-17 Synthon B.V. 4-Phenylpiperidine compounds

Also Published As

Publication number Publication date
FI112077B (fi) 2003-10-31
SK20262000A3 (sk) 2001-07-10
BE1012403A5 (fr) 2000-10-03
US6063927A (en) 2000-05-16
AU713131B3 (en) 1999-11-25
DK199900554A (da) 2000-01-03
PT970955E (pt) 2000-11-30
FR2780728A1 (fr) 2000-01-07
NL1011875C2 (nl) 2000-03-24
ITMI990866A1 (it) 2000-10-23
GB2352395B (en) 2004-02-11
NO991944L (no) 2000-01-03
EP1089996B1 (en) 2003-10-01
BE1011664A6 (fr) 1999-11-09
DE69900007D1 (de) 2000-09-07
IES20000894A2 (en) 2001-05-30
DE69911774T2 (de) 2004-08-05
IL140628A (en) 2004-06-20
GB9909505D0 (en) 1999-06-23
SI1020464T1 (en) 2001-12-31
AT3185U3 (de) 2000-01-25
GR1003350B (el) 2000-03-29
FIU990190U0 (fi) 1999-04-23
IES20000893A2 (en) 2001-05-30
EP0970955B1 (en) 2000-08-02
IES990343A2 (en) 2000-01-02
DE60000003D1 (de) 2001-08-09
ATE202777T1 (de) 2001-07-15
JP2002519422A (ja) 2002-07-02
US20010023253A1 (en) 2001-09-20
DE60000003T2 (de) 2002-03-21
GB2367003A (en) 2002-03-27
SE9901462L (enExample)
DE29907248U1 (de) 1999-09-09
BE1012420A6 (fr) 2000-10-03
PT102291A (pt) 2000-05-31
FI990922A0 (fi) 1999-04-23
WO2000001694A1 (en) 2000-01-13
HK1037877A1 (en) 2002-02-22
CH689805A5 (fr) 1999-11-30
KR20010053336A (ko) 2001-06-25
NO319030B1 (no) 2005-06-06
FI4209U1 (fi) 1999-11-10
DK200000390U1 (da) 2000-12-27
LU90388B1 (fr) 2001-01-29
EP1089996A1 (en) 2001-04-11
ES2157881T3 (es) 2001-09-01
GB0119695D0 (en) 2001-10-03
GB0216752D0 (en) 2002-08-28
IE20000633A1 (en) 2001-10-17
NL1012271A1 (nl) 1999-07-12
PT1089996E (pt) 2004-02-27
GR990100140A (el) 2000-03-31
AR011759A1 (es) 2000-09-13
FR2780728B1 (fr) 2001-02-16
DK199900234U4 (da) 2000-12-22
NL1012271C2 (nl) 1999-09-23
AU732211C (en) 2004-05-06
CN1315949A (zh) 2001-10-03
FR2802098A1 (fr) 2001-06-15
DK199900176U3 (da) 1999-08-13
EP0970955A1 (en) 2000-01-12
NZ509180A (en) 2001-06-29
IES81166B2 (en) 2000-05-31
ES2149044T3 (es) 2000-10-16
US20020035130A1 (en) 2002-03-21
PT1020464E (pt) 2001-10-30
AR018197A1 (es) 2001-10-31
DE69911774D1 (de) 2003-11-06
GB2352395A (en) 2001-01-31
GB0026487D0 (en) 2000-12-13
AU732211B2 (en) 2001-04-12
EP1020464A1 (en) 2000-07-19
CN1127502C (zh) 2003-11-12
AU2392899A (en) 2000-01-20
AU713877B3 (en) 1999-12-09
AU3619199A (en) 2000-01-24
GB2339428A (en) 2000-01-26
ATE195121T1 (de) 2000-08-15
BR9911682A (pt) 2001-12-26
IT1312540B1 (it) 2002-04-22
ES2209428T3 (es) 2004-06-16
ATE251155T1 (de) 2003-10-15
EP1020464B1 (en) 2001-07-04
DK1020464T3 (da) 2001-09-24
NO991944D0 (no) 1999-04-23
GB2336364B (en) 2000-05-10
NL1012272C1 (nl) 1999-07-12
NL1011874C1 (nl) 1999-07-12
GR3034328T3 (en) 2000-12-29
DK199900234U1 (da) 2000-12-22
IL140628A0 (en) 2002-02-10
SI0970955T1 (en) 2001-02-28
FI990922L (fi) 2000-01-03
HUP0102334A2 (hu) 2002-05-29
CH689805A8 (fr) 2000-02-29
NL1011875A1 (nl) 2000-01-07
GB9920332D0 (en) 1999-11-03
US20020193406A1 (en) 2002-12-19
ES2158778A1 (es) 2001-09-01
SE9901462A0 (sv) 2000-01-03
HUP0102334A3 (en) 2003-12-29
DK1089996T3 (da) 2004-02-09
DE69900007T2 (de) 2001-06-07
DE19918588A1 (de) 2000-01-27
ES2158778B1 (es) 2002-03-16
GB2336364A (en) 1999-10-20
CA2269999A1 (en) 2000-01-02
GR3036208T3 (en) 2001-10-31
SI1089996T1 (en) 2004-04-30
DK0970955T3 (da) 2000-10-09
AT3185U2 (de) 1999-11-25
TR200100054T2 (tr) 2001-06-21
EP1020463A1 (en) 2000-07-19
PL345214A1 (en) 2001-12-03
EP1288214A1 (en) 2003-03-05
IE990344A1 (en) 2000-05-03
SE9901462D0 (sv) 1999-04-23
PT102291B (pt) 2002-07-31

Similar Documents

Publication Publication Date Title
EP0970955B1 (en) Paroxetine methanesulfonate
AU2002100370A4 (en) Novel compound
US20010023252A1 (en) Novel compound
AU2001100025A4 (en) Novel compound
AU724845B3 (en) Novel compound
AU732558B3 (en) Novel compound
HK1030603A (en) Paroxetine methanesulfonate
HK1030773A (en) Paroxetine methanesulfonate
AU5430701A (en) Novel compound
IES83541Y1 (en) Paroxetine methanesulfonate
CZ20004924A3 (cs) Methansulfonat paroxetinu
MXPA01000307A (en) Paroxetine methanesulfonate

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)